Recent Updates
Recently added Catalysts
SPRB Positive Sentiment

Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

Key Takeaway: Spruce Biosciences will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference. CEO Javier Szwarcberg is scheduled for a fireside chat on November 10, 2026, in Boston. This event provides a platform to discuss the company's novel therapies for neurological disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious healthcare conference
  • Opportunity to discuss innovative therapies
  • Engagement with potential investors and stakeholders

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
6.4%
average across 4 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
SPR001
Phase 2 · Congenital Adrenal Hyperplasia

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026 at 11:30 a.m. ET in Boston, MA.Interested parties can

Frequently Asked Questions

When is the Guggenheim Healthcare Innovation Conference?

The conference is on November 10, 2026.

Who will represent Spruce Biosciences at the conference?

CEO Javier Szwarcberg will participate in the event.

Where will the conference take place?

The conference will be held in Boston, MA.

What is the focus of Spruce Biosciences?

The company focuses on therapies for neurological disorders.

Last updated: Nov 2, 2026